These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cost advantage of different cardioverter-defibrillator devices. Veenhuyzen GD J Am Coll Cardiol; 2006 Jul; 48(2):418-9; author reply 419. PubMed ID: 16843205 [No Abstract] [Full Text] [Related]
8. Heart-to-heart partnerships cut costs of cardiac products. Doyle FF; Donahue RE Mater Manag Health Care; 1997 Apr; 6(4):18, 20. PubMed ID: 10166585 [No Abstract] [Full Text] [Related]
9. Ethical and cost benefit issues of research involving patients with an implantable defibrillator. Pagé P Can J Cardiol; 1994 Apr; 10(3):339-41. PubMed ID: 8162532 [No Abstract] [Full Text] [Related]
10. Sudden death prevention with implantable devices. Passman R; Kadish A Circulation; 2007 Jul; 116(5):561-71. PubMed ID: 17664385 [No Abstract] [Full Text] [Related]
11. Should industry share a greater burden for the cost of device recalls? Lindsay BD Heart Rhythm; 2011 Aug; 8(8):1198-9. PubMed ID: 21683806 [No Abstract] [Full Text] [Related]
13. The Fidelis recall: how much pressure can the ICD world bear? Cannom DS; Fisher J Pacing Clin Electrophysiol; 2008 Oct; 31(10):1233-5. PubMed ID: 18811800 [No Abstract] [Full Text] [Related]
14. Cost-Effectiveness Related to Implantable Electronic Cardiac Devices: An Ever-Constant Concern. Camanho LEM Arq Bras Cardiol; 2024 Apr; 121(4):e20240185. PubMed ID: 38716991 [No Abstract] [Full Text] [Related]
15. Pacemaker implantation in the United States: an urgent need for answers. Vlietstra RE Pacing Clin Electrophysiol; 1998 Jan; 21(1 Pt 1):1-3. PubMed ID: 9474641 [No Abstract] [Full Text] [Related]
16. [Comment on NASPE recommendations for removal of permanently implanted, transvenous cardiac pacemaker and defibrillator electrodes]. Hemmer W; Fröhlig G; Markewitz A; Z Kardiol; 2002 Nov; 91(11):956-68. PubMed ID: 12442200 [No Abstract] [Full Text] [Related]
17. Group purchasing organizations: optimizing cardiac device selection, therapy delivery, and fiscal responsibility. Sweesy MW; Wilkoff BL; Smith KW; Holland JL Pacing Clin Electrophysiol; 2006 Dec; 29(12):1404-9. PubMed ID: 17201849 [TBL] [Abstract][Full Text] [Related]
18. Shelf price agreements: a novel approach to competitive bidding for arrhythmia therapy devices. Keast RK; Pelosi F; Morady F; Larin LR; Goldstein-Dunn J; Cox D; Michalak CG; Fetyko S; Denton TA; Eagle KA J Cardiovasc Manag; 2004; 15(5):12-5. PubMed ID: 15506010 [TBL] [Abstract][Full Text] [Related]
19. Funding for cardiac pacing and defibrillators in Calgary: the Robin Hood philosophy. Wyse DG; Gillis AM Pacing Clin Electrophysiol; 1993 Dec; 16(12):2305-9. PubMed ID: 7508608 [No Abstract] [Full Text] [Related]
20. [Sudden death. Implantable defibrillators. Value of the technology and economic impact]. Jazra C J Med Liban; 1999; 47(5):301-3. PubMed ID: 10887533 [No Abstract] [Full Text] [Related] [Next] [New Search]